Coeptis Therapeutics Holdings, Inc..
COEP.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Coeptis Therapeutics Holdings, Inc. is a pharmaceutical company focused on developing innovative therapies for cancer. The company's pipeline includes drug candidates targeting various types of cancer, including hematological malignancies and solid tumors. Coeptis Therapeutics utilizes various drug ...Show More
Better Health for All
30
Coeptis Therapeutics' entire business is devoted to developing innovative therapies for cancer and severe viral infections, indicating that 100% of its product portfolio aims to deliver exceptional health benefits. The company has no revenue from products with established negative health impacts, as its focus is solely on developing new, health-positive therapies.
1
In its Phase 1 clinical trials for DVX201, no dose-limiting toxicities, cytokine release syndrome, or infusion toxicities were observed in 17 patients across 25 infusions, demonstrating a perfect safety record to date.
2
The company is committed to developing cost-effective cellular treatments, emphasizing pool donor manufacturing for scalability and cost-effectiveness.
3
Coeptis is developing a novel allogeneic NK cell therapy platform (DVX201) and the GEAR™ Cell Therapy Platform, representing a significant investment in health innovation.
4
The company aims to address the 'tripledemic' of influenza, COVID-19, and RSV, demonstrating leadership during major health emergencies.
5
Fair Money & Economic Opportunity
0
No evidence available to assess Coeptis Therapeutics Holdings, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Coeptis Therapeutics Holdings, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Coeptis Therapeutics Holdings, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-30
The company's Board has adopted a Code of Business Conduct and Ethics that applies to all employees, officers, and directors, including executive and senior financial officers.
1
However, the policy's strength and enforcement, including training frequency or effectiveness metrics, are not detailed. Five out of seven board members are considered independent, as defined under Nasdaq listing requirements, which equates to approximately 71.4% of the board being conflict-free.
2
The company identified material weaknesses in its internal control over financial reporting.
3
Kind to Animals
-70
The company conducts preclinical studies in animals, specifically mice, for the development of cancer therapies.
1
There is no evidence of the company employing non-animal testing methods or having a formal animal testing policy.
2
No information is available regarding cruelty-free certifications, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, animal testing volume, investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.
3
No War, No Weapons
0
No evidence available to assess Coeptis Therapeutics Holdings, Inc. on No War, No Weapons.
Planet-Friendly Business
0
The provided articles focus on cybersecurity practices, corporate rebranding, and strategic shifts towards technology, or are inaccessible/directory pages for SEC filings. No specific, concrete data points related to environmental performance, sustainability targets, or any of the requested Planet-Friendly Business metrics were found.
1
Respect for Cultures & Communities
0
No specific data or metrics related to Coeptis Therapeutics Holdings, Inc. and its respect for cultures and communities were found in the provided articles.
1
The articles were either general opinion pieces, discussed unrelated topics, or were inaccessible, offering no concrete evidence to assess any of the defined KPIs.
2
Safe & Smart Tech
0
No evidence available to assess Coeptis Therapeutics Holdings, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding Coeptis Therapeutics Holdings, Inc.'s performance or initiatives related to waste management, product sustainability, or circular economy principles. The articles primarily focus on financial results, corporate transactions, and investor relations, without addressing any of the specific KPIs for the 'Zero Waste & Sustainable Products' value.